Browse the evidence

GLP-1-based therapies, particularly dual GLP-1/GIP agonists like tirzepatide, produce large, clinically meaningful reductions in AHI and cardiometabolic risk in obesity-associated OSA.

If you have obesity-related sleep apnea, ask your doctor about GLP-1/GIP agonists like tirzepatide. These medications can significantly reduce your apnea severity by reducing weight and metabolic load, offering a systemic treatment option.

Hypoglossal nerve stimulation (HNS) produces substantial, durable improvements in AHI and symptoms with high adherence, supported by randomized trials and real-world data.

If you have moderate-to-severe sleep apnea and cannot tolerate CPAP, ask about hypoglossal nerve stimulation (HNS). It is an implanted device that stimulates the tongue to keep the airway open, offering substantial and durable relief for the right candidate.

GLP-1 and GIP/GLP-1 agonists reduce systemic inflammation (hsCRP, IL-6) and improve metabolic parameters (HbA1c, blood pressure, lipids) in obese patients, contributing to overall cardiovascular risk reduction.

If you are obese, ask your doctor about GLP-1 agonists. They can significantly improve your blood pressure, blood sugar, and inflammation levels, reducing your overall risk of heart disease and stroke.

GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.

If you are struggling to lose weight on GLP-1 medications like liraglutide despite strict adherence, ask your doctor about pharmacogenetic testing for GLP1R variants. Your genetic makeup may dictate whether this specific drug is the right fit for you, helping you avoid ineffective treatments and switch to alternatives sooner.

Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.

Tirzepatide works differently than semaglutide by activating both GIP and GLP-1 receptors. This dual action may lead to greater fat loss and potentially fewer stomach side effects.

GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).

Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.

Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.

Newer 'triple-agonist' weight loss medications target three different hormonal pathways (GLP-1, GIP, and Glucagon) instead of just one. Clinical trials show these can lead to over 20% body weight loss, which is significantly higher than older single-target drugs. These are currently experimental and not yet widely available for general use.

Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.

If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.

Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.

For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.

Protein or amino acid supplementation combined with resistance exercise training in older adults produces a positive but minor effect on whole-body lean mass growth, while having minimal and inconsistent effects on muscle mass, strength, or functional capacity.

If you are an older adult doing resistance training, adding protein or amino acid supplements will likely help you gain a small amount of lean body mass (roughly 0.2-0.8 kg more than exercise alone). However, do not expect significant increases in strength, muscle size, or physical function from the supplement alone; the exercise is doing the heavy lifting. This benefit is most noticeable in frail or sarcopenic individuals, whereas those who are obese may see little to no benefit.

Nutritional interventions (protein, leucine, HMB, creatine) preserve or modestly increase lean mass in sarcopenia but fail to consistently restore muscle strength or physical function when applied in isolation.

Eat enough protein (at least 1.2g per kg of body weight daily) and consider creatine or HMB, but do not expect these supplements to fix your strength or balance on their own. You must combine them with resistance exercise to see functional benefits. Nutrition primes the muscle, but exercise builds the function.

During COVID-19 stay-at-home mandates, older adults with type 2 diabetes experienced significant weight loss (average 2.1%) rather than the weight gain often reported in younger populations.

If you are an older adult with type 2 diabetes, do not assume the pandemic shutdown will automatically cause weight gain. This study found that the majority of participants actually lost weight. However, those who did gain weight reported more negative impacts on their health and access to food, so monitoring your weight and mental well-being is still important.

Among older adults with type 2 diabetes, those who gained weight during the pandemic reported significantly more negative psychosocial and behavioral impacts than those who lost weight.

If you gained weight during the pandemic, you are not alone, but you may be experiencing more stress, sleep issues, or access problems than those who lost weight. Focus on addressing these specific barriers (food access, sleep) rather than just the scale number. If you lost weight, it was likely intentional and not associated with the negative mental health impacts seen in gainers.

Metabolic surgery (VSG/RYGB) alters gut hormone profiles by increasing GLP-1 and PYY while decreasing ghrelin, leading to reduced hunger and improved satiety, which aids in sustained weight loss and glucose control.

Surgery biologically reduces your hunger drive (ghrelin) and increases fullness signals (GLP-1/PYY), making it easier to maintain weight loss compared to dieting alone, which often triggers intense hunger.

Older adults (>30 years) significantly increase their energy intake from ultra-processed foods (UPFs) on weekends compared to weekdays, whereas younger adults (18-30 years) maintain consistent UPF consumption levels regardless of the day of the week.

If you are over 30, your weekend meals are likely driving your high ultra-processed food intake, whereas your weekday habits are stable. To improve your diet, focus your planning efforts specifically on Friday through Sunday. You do not need to change your weekday routine, as your data shows consistency there. Targeting the weekend window is the highest-yield intervention for this demographic.

Younger adults (18-30 years) consume ultra-processed foods (UPFs) in a continuous 'grazing' pattern throughout the day, with distinct peaks at 8 pm and 1 pm, whereas older adults follow conventional three-meal patterns with an additional morning peak.

If you are under 30, you likely snack on ultra-processed foods throughout the day rather than just at meals. Your intake peaks at 1 pm and 8 pm. To reduce UPF intake, focus on eliminating snacks during these specific hours, particularly the late evening peak, rather than just trying to eat 'less' overall.

Physical activity questionnaires (PAQs) and accelerometers demonstrate moderate validity for assessing total physical activity and moderate-to-vigorous physical activity (MVPA) in epidemiologic studies, with PAQs showing particularly strong correlations for vigorous activity.

For researchers and clinicians, using a well-designed physical activity questionnaire (PAQ) is a valid and scalable method for assessing moderate-to-vigorous physical activity in large groups, especially when gold-standard biomarkers like doubly labeled water are too costly. While accelerometers are useful, they may miss certain activities (like swimming or biking) and showed lower validity for vigorous activity compared to PAQs in this study. Combining methods or using validated questionnaires provides a robust estimate of physical activity levels for epidemiological purposes.

Consumption of fermented foods is associated with improved gut microbiome diversity, reduced inflammation, and metabolic health benefits, regardless of whether the product contains live microbes or is pasteurized.

Incorporate a variety of fermented foods (yogurt, kefir, sauerkraut, kimchi) into your diet. You do not need to worry if they are pasteurized; both live and dead microbes (postbiotics) offer benefits. If you have high blood pressure, choose lower-sodium options like yogurt or kefir over salty pickles, and consult your doctor if you are immunocompromised or have histamine intolerance.

Modifying the Health Star Rating algorithm to penalize ultra-processed foods (via negative points or score capping) significantly improves alignment with the NOVA classification system, but reduces alignment with current Australian Dietary Guidelines for core food categories like cereals and convenience foods.

Current front-of-pack labels may give a 'health halo' to ultra-processed foods that look nutritious on paper. If you are trying to eat whole foods, look for the NOVA classification or ingredient list complexity, not just the star rating. Be aware that some 'core' foods (like instant oatmeal or plant milks) are ultra-processed and might be penalized by new labeling systems, even if they are currently recommended.

Among people with HIV and prediabetes, higher BMI, larger waist circumference, hypertriglyceridemia, and lower CD4 counts are associated with a significantly increased risk of progression to type 2 diabetes.

If you have HIV and prediabetes, your waist size, body weight, and triglyceride levels are strong indicators of your risk of developing full diabetes. Additionally, maintaining a higher CD4 count is protective. You should prioritize lifestyle interventions aimed at weight loss and managing triglycerides, as these are modifiable risk factors that can help prevent progression to diabetes.

Low-carbohydrate diets improve cardiovascular risk markers (triglycerides, HDL, blood sugar, inflammation) and reduce 10-year ASCVD risk scores, despite potential increases in LDL-C in lean individuals.

If you are on a low-carbohydrate diet, expect improvements in triglycerides, HDL, and blood sugar. If your LDL-C rises, discuss with your provider whether it correlates with other risk factors, as overall cardiovascular risk may still decrease.

The 'keto flu' (flu-like symptoms during initial adaptation) can be avoided or alleviated by increasing sodium and mineral intake.

If you feel tired or have headaches when starting a low-carb diet, drink two cups of broth daily to replenish sodium and minerals. This simple step can prevent or alleviate the 'keto flu'.

New antidiabetic drugs with cardiovascular effects (GLP-1ra and SGLT2-in) are underutilized in primary care due to clinical inertia driven by physician uncertainty, guideline complexity, and patient-specific barriers, despite proven efficacy in reducing cardiovascular morbidity and mortality.

For family physicians managing T2D, prioritize prescribing GLP-1 receptor agonists (GLP-1ra) or SGLT2 inhibitors (SGLT2-in) for patients with established cardiovascular disease, heart failure, or chronic kidney disease, regardless of HbA1c levels. Address clinical inertia by using clinical decision support tools and clear guidelines that define specific indications for these drugs. Discuss cost and side effects (e.g., GI issues for GLP-1ra, genital infections for SGLT2-in) openly with patients to improve adherence.

Higher BMI categories (Class I-III obesity) are associated with adverse cardiometabolic profiles, including lower HDL-C, higher triglycerides, higher hsCRP, higher prevalence of hypertension and diabetes, lower physical activity (step counts), and higher mental health distress (PHQ-9/GAD-7 scores) compared to normal weight.

Maintaining a healthy weight is crucial for reducing cardiometabolic risk, but it is not the only factor. Individuals, especially those who are underweight or have obesity, should monitor blood pressure, lipids, inflammation (hsCRP), and mental health. Regular physical activity and managing stress are key components of overall health regardless of BMI category.